Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study.

Lappegård, Knut Tore (author): Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway

Kjellmo, Christian Abendstein (author): Division of Internal Medicine, Nordland Hospital, Bodø, Norway

Ljunggren, Stefan A (author): Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Arbets- och miljömedicin

Cederbrant, Karin (author): Swedish Toxicology Sciences Research Center, Södertälje, Sweden

Marcusson-Ståhl, Maritha (author): Swedish Toxicology Sciences Research Center, Södertälje, Sweden

Mathisen, Monica (author): Research Laboratory, Nordland Hospital, Bodø, Norway

Karlsson, Helen (author): Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Arbets- och miljömedicin

Hovland, Anders (author): Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway

(creator_code:org_t)

Elsevier BV, 2018
2018
English.
In: Transfusion and apheresis science. - : Elsevier BV. - 1473-0502 .- 1878-1683. ; 57:1, s. 91-96

Related links:: https://liu.diva-por... (primary) (Raw object); show more...; http://liu.diva-port...; https://urn.kb.se/re...; https://doi.org/10.1...; show less...

Abstract Subject headings

Lipoprotein apheresis and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are last therapeutic resorts in patients with familial hypercholesterolemia (FH). We explored changes in lipoprotein subclasses and high-density lipoprotein (HDL) function when changing treatment from lipoprotein apheresis to PCSK9 inhibition. We measured the levels of low-density lipoprotein (LDL) and HDL particle subclasses, serum amyloid A1 (SAA1), paraoxonase-1 (PON1) activity and cholesterol efflux capacity (CEC) in three heterozygous FH patients. Concentrations of all LDL particle subclasses were reduced during apheresis (large 68.0 ± 17.5 to 16.3 ± 2.1 mg/dL, (p = 0.03), intermediate 38.3 ± 0.6 to 5.0 ± 3.5 mg/dL (p = 0.004) and small 5.0 ± 2.6 to 0.2 ± 0.1 mg/dL (p = 0.08)). There were non-significant reductions in the LDL subclasses during evolocumab treatment. There were non-significant reductions in subclasses of HDL particles during apheresis, and no changes during evolocumab treatment. CEC was unchanged throughout the study, while the SAA1/PON1 ratio was unchanged during apheresis but decreased during evolocumab treatment. In conclusion, there were significant reductions in large and intermediate size LDL particles during apheresis, and a non-significant reduction in small LDL particles. There were only non-significant reductions in the LDL subclasses during evolocumab treatment.

By the author/editor: Lappegård, Knut ...; Kjellmo, Christi ...; Ljunggren, Stefa ...; Cederbrant, Kari ...; Marcusson-Ståhl, ...; Mathisen, Monica; show more...; Karlsson, Helen; Hovland, Anders; show less...

About the subject

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.